Guiding care through
clinically actionable results.

Providing actionable answers for treatment guidance and hereditary risk assessment

Colorectal cancer (CRC) is the third most common form of cancer in the U.S., with more than 150,000 new cases diagnosed each year. While sporadic colon cancers are more common, hereditary colon cancers are also frequent, and identification of these affects screening recommendations both for the individual and family members. 

Fewer than half the people found to have colorectal cancer are diagnosed at an early stage, when treatment is most effective. New therapies can reduce tumor size and prolong life, but they can also be costly and not work as intended. The results and interpretations from our laboratories provide clinically actionable results to guide treatment selection, ensuring every patient receives the medication most appropriate for care. In addition to guiding treatment, our testing also assesses risk for developing hereditary cancer syndrome. 


Enabling treatment decisions

Treatment options for colorectal cancer patients have expanded beyond standard chemotherapeutic agents and are leading to an increase in survival rates for individuals with advanced stage colorectal cancer. Both epidermal growth factor receptor (EGFR)-targeted therapy and immunotherapy are available to patients with CRC tumors with specific molecular features.

Current guidelines recommend RAS/RAF testing to identify patients unlikely to benefit from anti-EGFR therapy


Featured Digital Content

Subtext here.

Additional Resources

Webinar - Which molecular tests to order for colorectal cancer

This “Specialty Testing” webinar, presented by Rondell P. Graham, M.B.B.S., describes the utility of microsatellite instability testing in colorectal cancer care and discusses the limitation of various assays used to diagnose microsatellite instability.

Method for counting tumor budding in colorectal carcinoma could have immediate and powerful prognostic value

In a recent study, Mayo Clinic researchers, in collaboration with other institutions, have shown that “high” tumor budding in patients with colorectal carcinoma (CRC) is independently associated with a significantly worse prognosis.